問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Digestive System Department

Division of General Internal Medicine

更新時間：2023-09-19

蘇銘堯Su, Ming-Yao
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years

Recruiting Trial

9Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蘇銘堯

List

22Cases

2018-04-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2017-01-22 - 2023-12-22

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated5Sites

邱正堂
Linkou Chang Gung Medical Foundation

2018-06-01 - 2027-06-30

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2018-04-01 - 2020-04-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

周仁偉
China Medical University Hospital-Taipei

未分科

2018-04-01 - 2020-04-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2018-04-01 - 2020-04-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting5Sites

2017-09-01 - 2020-01-31

Phase II

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients with Active Ulcerative Colitis

  • Condition/Disease

    Ulcerative Colitis

  • Test Drug

    TJ301

Participate Sites
2Sites

Recruiting2Sites

邱正堂
Linkou Chang Gung Medical Foundation

Digestive System Department

2012-01-01 - 2014-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2012-01-01 - 2015-09-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

2012-01-01 - 2013-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Study ended4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB